Poor
Mostly Not Aligned
Patient Risk:
Low
Summary
Only one of the provided claims is supported by the supplied FDA label content (description/formulation). All other claims concern insurance/discounts/coupons and cost-driven prescribing logistics, which are absent from the provided label sections, yielding low overall alignment.
Category Scores
Accurate Statements
Abilify Mycite is aripiprazole tablets with an ingestible sensor.
Supported only in part by label citation for aripiprazole tablets (11 DESCRIPTION). The provided label section does not mention an ingestible sensor.
Unsupported Statements
Abilify Mycite is typically covered by commercial insurance.
Insurance coverage practices are not described in the supplied label sections.
A specific 'coupon' for Abilify Mycite depends on the manufacturer's current program and any pharmacy discount offers.
Coupon/program/discount terms are not described in the supplied label sections.
Copay cards/discount coupons work only for patients with commercial insurance.
The label provided contains no restrictions regarding payer type for coupons/discounts.
Copay cards/discount coupons often do not apply to government plans (Medicare/Medicaid).
The label provided contains no statements about government plan applicability for coupons/discounts.
Copay cards/discount coupons often do not apply if the prescription is covered in certain ways.
The label provided contains no statements about how coverage arrangements affect coupon/discount use.
Pharmacy staff can tell whether a plan allows the coupon/discount to be used at checkout.
Checkout/operational guidance about coupons/discounts is not described in the supplied label sections.
Manufacturer patient assistance programs may be available for eligible patients.
Patient assistance program availability is not described in the supplied label sections.
Pharmacy loyalty programs or cash-pay discounts may be used as alternatives when a coupon cannot be used.
Alternatives to manufacturer coupons/discounts are not described in the supplied label sections.
Switching to a lower-cost formulation requires the prescriber to agree.
The supplied label sections provided do not contain any requirement about prescriber agreement for cost-driven formulation switching.
Contradictions
Low
AI Statement
Abilify Mycite is aripiprazole tablets with an ingestible sensor.
Label Reference
11 DESCRIPTION
Important Omissions
In-label supported formulation details: the supplied label section confirms aripiprazole tablets and strengths, but does not confirm an ingestible sensor; the claim therefore lacks label-supported specificity for the sensor component.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims primarily concern insurance/coupons/discount logistics rather than drug safety, dosing, contraindications, or monitoring. The only partial formulation support concerns the sensor feature, which is not substantiated by the provided label section.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Not Aligned
Primary Issue
Most claims are about payer coverage, coupon/cash discount mechanics, and patient assistance logistics that are absent from the supplied FDA label sections.
Suggested Improvement
Restrict claims to content actually present in the FDA-approved label excerpt provided (e.g., aripiprazole tablet description and labeled indications/dosing/safety, if those sections are supplied). Remove or qualify insurance/coupon/cost-switching statements unless corresponding labeled content is provided.